Efficacy of divalproex therapy for schizoaffective disorder

Area of Science:

• Psychiatry
• Pharmacology
• Mental Health

Background:

• Schizoaffective disorder is a severe, lifelong mental illness with limited established pharmacologic treatments.
• Divalproex is a known effective treatment for bipolar disorder.
• The efficacy of divalproex as adjunctive therapy for schizoaffective disorder remains largely unknown.

Purpose of the Study:

• To investigate the effectiveness and tolerability of divalproex as adjunctive therapy in patients with schizoaffective disorder, bipolar type.
• To evaluate the impact of divalproex on clinical symptoms in this patient population.

Main Methods:

• A retrospective study was conducted on 20 patients diagnosed with schizoaffective disorder, bipolar type.
• Patients initiated divalproex therapy within the public mental health system.
• Clinical Global Impression Scale scores were used to assess patient improvement.

Main Results:

• 75% (15/20) of patients showed overall improvement in Clinical Global Impression Scale scores (p = 0.0001).
• No patients in the study worsened or discontinued divalproex due to side effects.
• The mean maximum divalproex dose was 1,150 mg, with a mean peak serum valproic acid level of 61 microg/mL.

Conclusions:

• Divalproex appears to be well-tolerated and effective as an adjunctive treatment for persistent schizoaffective disorder, bipolar type.
• These findings suggest divalproex may be a valuable therapeutic option for schizoaffective disorder, similar to its use in bipolar disorder.
• Further controlled prospective trials are necessary to confirm these preliminary results in patients with schizoaffective disorder.